JP2024531477A5 - - Google Patents

Info

Publication number
JP2024531477A5
JP2024531477A5 JP2024513014A JP2024513014A JP2024531477A5 JP 2024531477 A5 JP2024531477 A5 JP 2024531477A5 JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024531477 A5 JP2024531477 A5 JP 2024531477A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
hydrogen
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/115259 external-priority patent/WO2023025307A1/en
Publication of JP2024531477A publication Critical patent/JP2024531477A/ja
Publication of JP2024531477A5 publication Critical patent/JP2024531477A5/ja
Pending legal-status Critical Current

Links

JP2024513014A 2021-08-27 2022-08-26 Parp阻害剤としての置換三環式化合物およびその使用 Pending JP2024531477A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202111000443.7 2021-08-27
CN202111000443 2021-08-27
CN202111447991 2021-11-30
CN202111447991.4 2021-11-30
CN202210274490 2022-03-18
CN202210274490.9 2022-03-18
PCT/CN2022/115259 WO2023025307A1 (en) 2021-08-27 2022-08-26 Substituted tricyclic compounds as parp inhibitors and use thereof

Publications (2)

Publication Number Publication Date
JP2024531477A JP2024531477A (ja) 2024-08-29
JP2024531477A5 true JP2024531477A5 (cg-RX-API-DMAC7.html) 2025-08-20

Family

ID=85322483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513014A Pending JP2024531477A (ja) 2021-08-27 2022-08-26 Parp阻害剤としての置換三環式化合物およびその使用

Country Status (10)

Country Link
US (1) US20240368169A1 (cg-RX-API-DMAC7.html)
EP (1) EP4392425B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531477A (cg-RX-API-DMAC7.html)
KR (1) KR20240053612A (cg-RX-API-DMAC7.html)
CN (1) CN117980307A (cg-RX-API-DMAC7.html)
AU (1) AU2022334408A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230491A1 (cg-RX-API-DMAC7.html)
IL (1) IL311024A (cg-RX-API-DMAC7.html)
MX (1) MX2024002425A (cg-RX-API-DMAC7.html)
WO (1) WO2023025307A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
AU2023229992A1 (en) * 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
CN117263943B (zh) * 2022-09-09 2026-06-02 轩竹生物科技股份有限公司 聚(adp核糖)聚合酶选择性抑制剂
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作parp1抑制劑的化合物、其用途及包含其之組合物
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
IL329017A (en) * 2023-12-13 2026-08-01 Eikon Therapeutics Inc Process for preparing modified tricyclic materials
CN120923504A (zh) 2024-05-09 2025-11-11 上海瑛派药业有限公司 Parp1抑制剂的晶型及其制备

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
MX2009007053A (es) * 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
WO2011006803A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
WO2013014038A1 (en) 2011-07-26 2013-01-31 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
CN112028829B (zh) 2020-09-25 2022-02-15 温州大学 一种合成菲啶酮类化合物的方法
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
PT4497438T (pt) * 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações

Similar Documents

Publication Publication Date Title
UA126421C2 (uk) Інгібітори pd-1/pd-l1
JP2022507025A5 (cg-RX-API-DMAC7.html)
RU2018130330A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
CN108430473B (zh) 抗增殖化合物以及其药物组合物和用途
JP7491220B2 (ja) 免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療
CA3068591A1 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
JP2017520607A5 (cg-RX-API-DMAC7.html)
JP2021529172A5 (cg-RX-API-DMAC7.html)
JP2025508122A5 (cg-RX-API-DMAC7.html)
JP2015536994A5 (cg-RX-API-DMAC7.html)
CN107864625A (zh) 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
KR20200105662A (ko) 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체
KR102936318B1 (ko) 소세포폐암의 병용 치료용 퀴놀린 유도체
AU2012229266A1 (en) Combination therapies for hematologic malignancies
JP2024513538A5 (cg-RX-API-DMAC7.html)
CN111836621A (zh) 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法
KR20240124921A (ko) 약학적 조성물 및 이의 용도
JP7293108B2 (ja) Axl阻害剤とEGFRチロシンキナーゼ阻害薬との併用治療法
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
CA3054249A1 (en) Combinations of copanlisib with anti-pd-1 antibody
US20240342157A1 (en) Bak activators, pharmaceutical compositions, and uses in treating cancer
WO2024229440A2 (en) Methods of treating cancer using mdm2 inhibitors and compositions related thereto